department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Monoferric · pharmadog

pharmadog
drugs
Monoferric

drug

patient view →

ferric derisomaltose

Marketedupdated 2mo ago

by Pharmacosmos Therapeutics Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Monoferric

generic

ferric derisomaltose

indication

Iron Deficiency Anemia

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 2h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Mar 25, 2029

~2.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (15)

Jun 22, 2036method-of-use (U-3594)US 11633489
Jun 22, 2036method-of-use (U-3594)US 11633489
Jun 22, 2036method-of-use (U-3594)US 11633489
Aug 14, 2029compositionUS 88153013.1y
Aug 14, 2029compositionUS 88153013.1y
Aug 14, 2029compositionUS 88153013.1y
Mar 25, 2029compositionUS 104148312.7y
Mar 25, 2029compositionUS 104148312.7y
Mar 25, 2029compositionUS 104148312.7y
Mar 25, 2029compositionUS 118515042.7y
Mar 25, 2029compositionUS 118515042.7y
Mar 25, 2029compositionUS 118515042.7y
Mar 25, 2029compositionUS 120309622.7y
Mar 25, 2029compositionUS 120309622.7y
Mar 25, 2029compositionUS 120309622.7y

Trials studying ferric derisomaltose

phase4Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)completedn=65
phase3Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemiarecruitingn=200
phase3Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failurerecruitingn=1,900
phase4The Effects of Ferric Derisomaltose on Postoperative Anemia in Spinal Deformity Surgeryrecruitingn=120
phase4Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patientsrecruitingn=310
phase4A Clinical Trial Assessing the Efficacy of Intravenous Iron for the Treatment of Anemia Following Cardiac Surgerycompletedn=110